QUANTA-CLOUD-TECHNOLOGY
30.5.2022 06:02:10 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, will showcase its cutting-edge High-performance Computing (HPC) and AI solutions with vertical applications at the ISC High Performance Conference 2022 , from May 29 to June 2 in Hamburg, Germany at Booth D412 . These unique solutions combine QCT’s advanced hardware infrastructures with software technologies to help build scalable, converged HPC and AI environments across many industries while shortening the time to implement projects so researchers can fully concentrate on their research.
QCT will showcase the following solutions and servers that drive faster time-to-value:
- QCT Platform on Demand (QPOD): QPOD is a workload-driven and purpose-built solution for academia, research institutes, or medical centers, fully integrated with hardware infrastructures, cluster deployment, monitoring and management tools to fulfill HPC and AI workloads. On top of the infrastructure, QCT has also worked with application ISVs to ensure the solution is pre-configured and pre-validated for HPC applications.
- High Performance Storage: Enabled by Intel® Optane™ persistent memory, Distributed Asynchronous Object Storage (DAOS) offers dramatic improvements to storage I/O to accelerate HPC, AI, analytics, and cloud projects. QCT’s advanced storage servers equipped with the DAOS open-source software-defined object store have also brought world-class IOPS and bandwidth as they have ranked on the IO500 and 10-Node Challenge during SC21.
- QuantaGrid D53X-1U: a 1U compute node server optimized by 3rd Gen Intel® Xeon® Scalable processors with built-in AI Accelerators and Intel® Optane™ persistent memory 200 series to propel DAOS and enable AI, HPC and virtualization workloads.
- QuantaGrid D53XQ-2U: a 2U server that benefits from DAOS fueled by Intel® Optane™ persistent memory on the Intel Xeon Scalable platform and equipped with acceleration card expansion slots to power AI, analytics, bioscience, HPC, and even cloud computing workloads.
For more information on QCT’s high-performance storage product line, join QCT’s speaking session titled “Innovative High-performance Storage for AI/HPC in the Exascale Era” at the HPC Solutions Forum (Hall H, Booth J901) on May 31 at 2:00 pm. Our Technical Manager and Solution Architect, Grover Hwang, will give a deep dive on using DAOS to achieve less I/O wait and lower latency when running real-world AI/HPC applications.
“QCT is excited to bring our latest HPC solutions built for compute and graphic-intensive workloads to ISC 2022,” said QCT President Mike Yang. “As an infrastructure builder, QCT leverages our robust R&D capabilities and strong software ecosystem support to tune our solutions all the way from hardware to the software stack, accelerating digital transformation in fields across weather forecasting, NGS, molecular dynamics and more.”
Visit QCT Booth D412 at ISC22 and http://www.qct.io to learn more.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. http://www.qct.io
Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom